The pathogenesis of bacterial endophthalmitis

Endophthalmitis

Volumn , Issue , 2016, Pages 17-47

  Parkunan, Salai Madhumathi ^a   Callegan, Michelle C ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84978204209     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-29231-1_2     Document Type: Chapter

References (244)

1. Miller JJ, Scott IU, Flynn Jr HW, et al. Acute-onset endophthalmitis after cataract surgery (2000-2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am J Ophthalmol. 2005;139:983-7.
2. Lalwani GA, Flynn Jr HW, Scott IU, et al. Acute-onset endophthalmitis after clear corneal cataract surgery (1996-2005). Clinical features, causative organisms, and visual acuity outcomes. Ophthalmology. 2008;115:473-6.
3. West E, Behrens A, McDonnell P, et al. The incidence of endophthalmitis after cataract surgery among the US Medicare population increased between 1994 and 2001. Ophthalmology. 2005;112:1388-94.
4. World Health Organization. What are the VISION 2020 objectives for cataract intervention? http://www.who.int/blindness/causes/priority/en/index1.html. Accessed 10 May 2015
5. Endophthalmitis Study Group, European Society of Cataract & Refractive Surgeons. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg. 2007;33:978-88.
6. Taban M, Behrens A, Newcomb RL, et al. Acute endophthalmitis following cataract surgery: a systematic review of the literature. Arch Ophthalmol. 2005;123:613-20.
7. Endophthalmitis Vitrectomy Study Group. Microbiologic factors and visual outcome in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol. 1996;122(6):830-46.
8. Williams GA. IVT injections: health policy implications. Rev Ophthalmol. 2014;21:62-4.
9. Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina. 2009;29:875-912.
10. Diago T, McCannel CA, Bakri SJ, et al. Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina. 2009;29:601-5.
11. Klein KS, Walsh MK, Hassan TS, et al. Endophthalmitis after anti-VEGF injections. Ophthalmology. 2009;116:1225.e1.
12. Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol. 2010;21:178-83.
13. McGwin G, Xie A, Owsley C. The rate of eye injury in the United States. Arch Ophthalmol. 2005;123:970-6.
14. Mieler W. Overview of ocular trauma. In: Principles and practice of ophthalmology. 2nd ed. Saunders; Philadelphia. 1999. p. 5179.
15. Jonas JB, Knorr HL, Budde WM. Prognostic factors in ocular injuries caused by intraocular or retrobulbar foreign bodies. Ophthalmology. 2000;107:823-8.
16. Thompson JT, Parver LM, Enger CL, et al. Infectious endophthalmitis after penetrating injuries with retained intraocular foreign bodies. Ophthalmology. 1993;100:1468-74.
17. Thompson WS, Rubsamen PE, Flynn Jr HW, et al. Endophthalmitis after penetrating trauma. Risk factors and visual acuity outcomes. Ophthalmol. 1995;102:1696-701.
18. Verbraeken H, Rysselaere M. Post-traumatic endophthalmitis. Eur J Ophthalmol. 1993;4(1):1-5.
19. Jackson TL, Paraskevopoulos T, Georgalas I. Systematic review of 342 cases of endogenous bacterial endophthalmitis. Surv Ophthalmol. 2014;59(6):627-35.
20. Jackson TL, Eykyn SJ, Graham EM, et al. Endogenous bacterial endophthalmitis: a 17-year prospective series and review of 267 reported cases. Surv Ophthalmol. 2003;48(4):403-23.
21. Group EVS. Results of the Endophthalmitis Vitrectomy Study: a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol. 1995;113(12):1479.
22. Gentile RC, Shukla S, Shah M, et al. Microbiological spectrum and antibiotic sensitivity in endophthalmitis: a 25-year review. Ophthalmology. 2014;121(8):1634-42.
23. Das T, Choudhury K, Sharma S, et al. Clinical profile and outcome in Bacillus endophthalmitis. Ophthalmology. 2001;108:1819-25.
24. Das T, Kunimoto DY, Sharma S, et al. Relationship between clinical presentation and visual outcome in postoperative and posttraumatic endophthalmitis in south central India. Indian J Ophthalmol. 2005;53:5-16.
25. David DB, Kirkby GR, Noble BA. Bacillus cereus endophthalmitis. Br J Ophthalmol. 1994;78:577-80.
26. Davey RT, Tauber WB. Posttraumatic endophthalmitis: the emerging role of Bacillus cereus infection. Rev Infect Dis. 1987;9:110-23.
27. Callegan MC, Kane ST, Cochran DC, et al. Virulence factor profiles and antimicrobial susceptibilities of ocular Bacillus isolates. Curr Eye Res. 2006;31:693-702.
28. Tandon A, Tay-Kearney ML, Metcalf C, et al. Bacillus circulans endophthalmitis. Clin Exp Ophthalmol. 2001;29(2):92-3.
29. Long C, Liu B, Xu C, et al. Causative organisms of post-traumatic endophthalmitis: a 20-year retrospective study. BMC Ophthalmol. 2014;14(1):34.
30. Padhi TR, Sharma S, Das S, et al. Bacillus licheniformis as a cause of delayed-onset recurrent pseudophakic endophthalmitis- a rare case report. Retin Cases Brief Rep. 2012;6(1):43-5.
31. Sahu C, Kumar K, Sinha MK, et al. Review of endogenous endophthalmitis during pregnancy including case series. Int Ophthalmol. 2013;33(5):611-8.
32. Turnbull PCB. Bacillus cereus toxins. Pharmacol Ther. 1981;13(3):453-505.
33. Granum PE. Bacillus cereus and its toxins. J Appl Bacteriol Symp Suppl. 1994;76(S23):61S-6.
34. Granum PE, Lund T. Bacillus cereus and its food poisoning toxins. FEMS Microbiol Lett. 1997;157(2):223-8.
35. Beecher DJ, Wong ACL. Tripartite hemolysin BL from Bacillus cereus. Hemolytic analysis of component interaction and model for its characteristic paradoxical zone phenomenon. J Biol Chem. 1997;272:233-9.
36. Beecher DJ, Pulido JS, Barney NP, et al. Extracellular virulence factors in Bacillus cereus endophthalmitis: methods and implication of involvement of hemolysin BL. Infect Immun. 1995;63(2):632-9.
37. Callegan MC, Jett BD, Hancock LE, et al. Role of hemolysin BL in the pathogenesis of extraintestinal Bacillus cereus infection assessed in an endophthalmitis model. Infect Immun. 1999;67(7):3357-66.
38. Beecher DJ, Olsen TW, Somers EB, et al. Evidence for contribution of tripartite hemolysin BL, phosphatidylcholine-preferring phospholipase C, and collagenase to virulence of Bacillus cereus endophthalmitis. Infect Immun. 2000;68(9):5269-76.
39. Callegan MC, Cochran DC, Kane ST, et al. Contribution of membrane-damaging toxins to Bacillus endophthalmitis pathogenesis. Infect Immun. 2002;70(10):5381-9.
40. Agaisse H, Gominet M, Økstad OA, et al. PlcR is a pleiotropic regulator of extracellular virulence factor gene expression in Bacillus thuringiensis. Mol Microbiol. 1999;32(5):1043-53.
41. Callegan MC, Kane ST, Cochran DC, et al. Relationship of plcR-regulated factors to Bacillus endophthalmitis virulence. Infect Immun. 2003;71(6):3116-24.
42. Moyer AL, Ramadan RT, Thurman J, et al. Bacillus cereus induces permeability of an in vitro blood-retina barrier. Infect Immun. 2008;76(4):1358-67.
43. Callegan MC, Booth MC, Jett BD, et al. Pathogenesis of gram-positive bacterial endophthalmitis. Infect Immun. 1999;67(7):3348-56.
44. Sanders ME, Norcross EW, Robertson ZM, et al. The Streptococcus pneumoniae capsule is required for full virulence in pneumococcal endophthalmitis. Invest Ophthalmol Vis Sci. 2011;52(2):865-72.
45. Callegan MC, Kane ST, Cochran DC, et al. Bacillus endophthalmitis: roles of bacterial toxins and motility during infection. Invest Ophthalmol Vis Sci. 2005;46(9):3233-8.
46. Callegan MC, Novosad BD, Ramirez R, et al. Role of swarming migration in the pathogenesis of Bacillus endophthalmitis. Invest Ophthalmol Vis Sci. 2006;47(10):4461-7.
47. Scott IU, Loo RH, Flynn HW, et al. Endophthalmitis caused by Enterococcus faecalis: antibiotic selection and treatment outcomes. Ophthalmology. 2003;110(8):1573-7.
48. Schönfeld CL. Recurrent endophthalmitis after trabeculectomy for glaucoma: importance of timely filtering bleb coverage for the conjunctiva. Case Rep Ophthalmol. 2012; 3(3):360.
49. Ciulla TA, Beck AD, Topping TM, et al. Blebitis, early endophthalmitis, and late endophthalmitis after glaucoma-filtering surgery. Ophthalmology. 1997;104(6):986-95.
50. Jacobs DJ, Leng T, Flynn Jr HW. Delayed-onset bleb-associated endophthalmitis: presentation and outcome by culture result. Clin Ophthalmol. 2011;5:739-44.
51. Yamamoto B, Kuwayama Y, Kano K. Clinical features of bleb-related infection: a 5-year survey in Japan. Acta Ophthalmol. 2013;91:619-24.
52. Morris Jr JG, Shay DK, Hebden JN, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin: establishment of endemicity in a university medical center. Ann Intern Med. 1995;123:250-9.
53. Boyce JM, Opal SM, Chow JW, et al. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol. 1994;32:1148-53.
54. Quale J, Landman D, Saurina G, et al. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis. 1996;23:1020-5.
55. Boyce JM, Mermel LA, Zervos MJ, et al. Controlling vancomycin-resistant enterococci. Infect Control Hosp Epidemiol. 1995;16:634-7.
56. Tang CW, Cheng CK, Lee TS. Community-acquired bleb-related endophthalmitis caused by vancomycin-resistant enterococci. Can J Ophthalmol. 2007;42(3):477-8.
57. Brock TD, Davie JM. Probable identity of a group D hemolysin with a bacteriocine. J Bacteriol. 1963;86(4):708-12.
58. Booth MC, Bogie CP, Sahl HG, et al. Structural analysis and proteolytic activation of Enterococcus faecalis cytolysin, a novel lantibiotic. Mol Microbiol. 1996;21(6):1175-84.
59. Ike Y, Hashimoto H, Clewell DB. High incidence of hemolysin production by Enterococcus (Streptococcus) faecalis strains associated with human parenteral infections. J Clin Microbiol. 1987;25:1524-8.
60. Ike Y, Clewell DB, Segarra RA, et al. Genetic analysis of the pAD1 hemolysin/bacteriocin determinant in Enterococcus faecalis: Tn917 insertional mutagenesis and cloning. J Bacteriol. 1990;172:155-63.
61. Libertin CR, Dumitru R, Stein DS. The hemolysin/bacteriocin produced by enterococci is a marker of pathogenicity. Diagn Microbiol Infect Dis. 1992;15(2):115-20.
62. Kreft B, Marre R, Schramm U, et al. Aggregation substance of Enterococcus faecalis mediates adhesion to cultured renal tubular cells. Infect Immun. 1992;60:25-30.
63. Chow JW, Thal LA, Perri MB, et al. Plasmid-associated hemolysin and aggregation substance production contribute to virulence in experimental enterococcal endocarditis. Antimicrob Agents Chemother. 1993;37:2474-7.
64. Huycke MM, Gilmore MS. Frequency of aggregation substance and cytolysin genes among enterococcal endocarditis isolates. Plasmid. 1995;34(2):152-6.
65. Guzman CA, Pruzzo C, LiPira G, et al. Role of adherence in pathogenesis of Enterococcus faecalis urinary tract infection and endocarditis. Infect Immun. 1989;57:1834-8.
66. Shankar V, Baghdayan AS, Huycke MM, et al. Infection-derived Enterococcus faecalis strains are enriched in esp, a gene encoding a novel surface protein. Infect Immun. 1999;67:193-200.
67. Shankar N, Baghdayan AS, Gilmore MS. Modulation of virulence within a pathogenicity island in vancomycin-resistant Enterococcus faecalis. Nature. 2002;417(6890):746-50.
68. Coburn PS, Gilmore MS. The Enterococcus faecalis cytolysin: a novel toxin active against eukaryotic and prokaryotic cells. Cell Microbiol. 2003;5(10):661-9.
69. Coburn PS, Pillar CM, Jett BD, et al. Enterococcus faecalis senses target cells and in response expresses cytolysin. Science. 2004;306(5705):2270-2.
70. Haas W, Shepard BD, Gilmore MS. Two-component regulator of Enterococcus faecalis cytolysin responds to quorum-sensing autoinduction. Nature. 2002;415(6867):84-7.
71. Jett BD, Jensen HG, Nordquist RE, et al. Contribution of the pAD1-encoded cytolysin to the severity of experimental Enterococcus faecalis endophthalmitis. Infect Immun. 1992;60(6):2445-52.
72. Booth MC, Hatter KL, Miller D, et al. Molecular epidemiology of Staphylococcus aureus and Enterococcus faecalis in endophthalmitis. Infect Immun. 1998;66(1):356-60.
73. Engelbert M, Mylonakis E, Ausubel FM, et al. Contribution of gelatinase, serine protease, and fsr to the pathogenesis of Enterococcus faecalis endophthalmitis. Infect Immun. 2004;72(6):3628-33.
74. Qin X, Singh KV, Weinstock GM, et al. Characterization of fsr, a regulator controlling expression of gelatinase and serine protease in Enterococcus faecalis OG1RF. J Bacteriol. 2001;183:3372-82.
75. Qin X, Singh KV, Weinstock GM, et al. Effects of Enterococcus faecalis fsr genes on production of gelatinase and a serine protease and virulence. Infect Immun. 2000;68:2579-86.
76. Nakayama J, Cao Y, Horii T, et al. Gelatinase biosynthesis-activating pheromone: a peptide lactone that mediates a quorum sensing in Enterococcus faecalis. Mol Microbiol. 2001;41:145-54.
77. Mylonakis E, Engelbert M, Qin X, et al. The Enterococcus faecalis fsrB gene, a key component of the fsr quorum-sensing system, is associated with virulence in the rabbit endophthalmitis model. Infect Immun. 2002;70(8):4678-81.
78. Galli D, Lottspeich F, Wirth R. Sequence analysis of Enterococcus faecalis aggregation substance encoded by the sex pheromone plasmid pAD1. Mol Microbiol. 1990;4:895-904.
79. Süßmuth SD, Muscholl-Silberhorn A, Wirth R, et al. Aggregation substance promotes adherence, phagocytosis, and intracellular survival of Enterococcus faecalis within human macrophages and suppresses respiratory burst. Infect Immun. 2000;68(9):4900-6.
80. Jett BD, Atkuri RV, Gilmore MS. Enterococcus faecalis localization in experimental endophthalmitis: role of plasmid-encoded aggregation substance. Infect Immun. 1998;66(2):843-8.
81. Ness T, Schneider C. Endogenous endophthalmitis caused by methicillin-resistant Staphylococcus aureus (MRSA). Retina. 2009;29(6):831-4.
82. Tang HHY, Yip PP, Woo CF, et al. Methicillin-resistant Staphylococcus aureus endophthalmitis after phacoemulsification in a continuous ambulatory peritoneal dialysis patient. J Cataract Refract Surg. 2008;34(10):1806-8.
83. Ho V, Ho LY, Ranchod TM, et al. Endogenous methicillin-resistant Staphylococcus aureus endophthalmitis. Retina. 2011;31(3):596-601.
84. World Health Organization, Prevention of Blindness and Visual Impairment. http://www.who.int/blindness/causes/priority/en/index1.html. Accessed 10 May 2015.
85. Centers for Disease Control and Prevention, Vision Health Initiative. http://www.cdc.gov/visionhealth/basic_information/eye_disorders.htm. Accessed 12 May 2015.
86. World Health Organization, Blindness: Vision 2020 - control of major blinding diseases and disorders. http://www.who.int/mediacentre/factsheets/fs214/en/. Accessed 13 May 2015.
87. Kodjikian L, Beby F, Rabilloud M, et al. Influence of intraocular lens material on the development of acute endophthalmitis after cataract surgery. Eye. 2008;22(2):184-93.
88. Schanzlin DJ, Goldberg DB, Brown SI. Staphylococcus epidermidis endophthalmitis following intraocular lens implantation. Br J Ophthalmol. 1980;64(9):684-6.
89. Bannerman TL, Rhoden DL, McAllister SK, et al. The source of coagulase-negative staphylococci in the Endophthalmitis Vitrectomy Study: a comparison of eyelid and intraocular isolates using pulsed-field gel electrophoresis. Arch Ophthalmol. 1997;115(3):357-61.
90. Chen X, Adelman RA. Microbial spectrum and resistance patterns in endophthalmitis: a 21-Year (1988-2008) review in Northeast United States. J Ocul Pharmacol Ther. 2012;28(4):329-34.
91. Benz MS, Scott IU, Flynn HW, et al. Endophthalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases. Am J Ophthalmol. 2004;137(1):38-42.
92. Ziebuhr W, Hennig S, Eckart M, et al. Nosocomial infections by Staphylococcus epidermidis: how a commensal bacterium turns into a pathogen. Int J Antimicrob Agents. 2006;28:14-20.
93. Raad I, Alrahwan A, Rolston K. Staphylococcus epidermidis: emerging resistance and need for alternative agents. Clin Infect Dis. 1998;26(5):1182-7.
94. Prasad S, Nayak N, Satpathy G, et al. Biofilm: the haven for Staphylococcus epidermidis in post-operative endophthalmitis. J Clin Exp Ophthalmol. 2014;5(350):2.
95. Elder MJ, Stapleton F, Evans E, et al. Biofilm-related infections in ophthalmology. Eye. 1995;9(1):102-9.
96. Okajima Y, Kobayakawa S, Tsuji A, et al. Biofilm formation by Staphylococcus epidermidis on intraocular lens material. Invest Ophthalmol Vis Sci. 2006;47(7):2971-5.
97. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol. 2004;2(2):95-108.
98. Mack D, Fischer W, Krokotsch A, et al. The intercellular adhesin involved in biofilm accumulation of Staphylococcus epidermidis is a linear beta-1, 6-linked glucosaminoglycan: purifi - cation and structural analysis. J Bacteriol. 1996;178(1):175-83.
99. Sadovskaya I, Vinogradov E, Flahaut S, et al. Extracellular carbohydrate-containing polymers of a model biofilm-producing strain, Staphylococcus epidermidis RP62A. Infect Immun. 2005;73(5):3007-17.
100. McKenney D, Hübner J, Muller E, et al. The ica locus of Staphylococcus epidermidis encodes production of the capsular polysaccharide/adhesin. Infect Immun. 1998;66(10):4711-20.
101. Cafiso V, Bertuccio T, Santagati M, et al. Presence of the ica operon in clinical isolates of Staphylococcus epidermidis and its role in biofilm production. Clin Microbiol Infect. 2004;10(12):1081-8.
102. Maira-Litran T, Kropec A, Abeygunawardana C, et al. Immunochemical properties of the staphylococcal poly-N-acetylglucosamine surface polysaccharide. Infect Immun. 2002;70:4433-40.
103. Juárez-Verdayes MA, Ramón-Peréz ML, Flores-Páez LA, et al. Staphylococcus epidermidis with the icaA−/icaD−/IS256− genotype and protein or protein/extracellular-DNA biofilm is frequent in ocular infections. J Med Microbiol. 2013;62(Pt 10):1579-87.
104. Heilmann C, Hussain M, Peters G, et al. Evidence for autolysin-mediated primary attachment of Staphylococcus epidermidis to a polystyrene surface. Mol Microbiol. 1997;24(5):1013-24.
105. Nilsson M, Frykberg L, Flock JI, et al. A fibrinogen-binding protein of Staphylococcus epidermidis. Infect Immun. 1998;66:2666-73.
106. Guo B, Zhao X, Shi Y, et al. Pathogenic implication of a fibrinogen-binding protein of Staphylococcus epidermidis in a rat model of intravascular-catheter-associated infection. Infect Immun. 2007;75:2991-5.
107. Gotz F. Staphylococcus and biofilms. Mol Microbiol. 2002;43:1367-78.
108. Otto M. Staphylococcus aureus and Staphylococcus epidermidis peptide pheromones produced by the accessory gene regulator agr system. Peptides. 2001;22:1603-8.
109. Vuong C, Gerke C, Somerville GA, et al. Quorum-sensing control of biofilm factors in Staphylococcus epidermidis. J Infect Dis. 2003;188(5):706-18.
110. Xu L, Li H, Vuong C, et al. Role of the luxS quorum-sensing system in biofilm formation and virulence of Staphylococcus epidermidis. Infect Immun. 2006;74(1):488-96.
111. Meredith TA, Trabelsi A, Miller MJ, et al. Spontaneous sterilization in experimental Staphylococcus epidermidis endophthalmitis. Invest Ophthalmol Vis Sci. 1990;31(1):181-6.
112. Booth MC, Atkuri RV, Nanda SK, et al. Accessory gene regulator controls Staphylococcus aureus virulence in endophthalmitis. Invest Ophthalmol Vis Sci. 1995;36(9):1828-36.
113. Booth MC, Cheung AL, Hatter KL, et al. Staphylococcal accessory regulator (sar) in conjunction with agr contributes to Staphylococcus aureus virulence in endophthalmitis. Infect Immun. 1997;65(4):1550-6.
114. Leid JG, Costerton JW, Shirtliff ME, et al. Immunology of Staphylococcal biofilm infections in the eye: new tools to study biofilm endophthalmitis. DNA Cell Bio. 2002;21(5-6):405-13.
115. Kowalski RP, Romanowski EG, Mah FS, et al. Intracameral Vigamox® (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model. Am J Ophthalmol. 2005;140(3):497-e1.
116. Kowalski RP, Romanowski EG, Mah FS, et al. A comparison of moxifloxacin and levofloxacin topical prophylaxis in a fluoroquinolone-resistant Staphylococcus aureus rabbit model. Jpn J Ophthalmol. 2008;52(3):211-6.
117. Chiquet C, Pechinot A, Creuzot-Garcher C, et al. Acute postoperative Endophthalmitis caused by Staphylococcus lugdunensis. J Clin Microbiol. 2007;45(6):1673-8.
118. Affeldt JC, Flynn HW, Forster RK, et al. Microbial endophthalmitis resulting from ocular trauma. Ophthalmology. 1987;94:407-13.
119. Olson JC, Flynn HW, Forster RK. Results in the treatment of postoperative endophthalmitis. Ophthalmology. 1983;90:692-9.
120. Shrader SK, Band JD, Lauter CB, et al. The clinical spectrum of endophthalmitis: incidence, predisposing factors, and features influencing outcome. J Infect Dis. 1990;162:115-20.
121. Kattan HM, Flynn HW, Pflugfelder SD, et al. Nosocomial endophthalmitis survey: current incidence of infection after intraocular surgery. Ophthalmology. 1991;98:227-38.
122. Major JC, Engelbert M, Flynn HW, et al. Staphylococcus aureus endophthalmitis: antibiotic susceptibilities, methicillin resistance, and clinical outcomes. Am J Ophthalmol. 2010;149(2):278-83.
123. Marangon FB, Miller D, Muallem MS, et al. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. Am J Ophthalmol. 2004;137(3):453-8.
124. Blomquist PH. Methicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006;104:322.
125. Freidlin J, Acharya N, Lietman TM, et al. Spectrum of eye disease caused by methicillinresistant Staphylococcus aureus. Am J Ophthalmol. 2007;144(2):313-5.
126. Chiquet C, Maurin M, Altayrac J, et al. Correlation between clinical data and antibiotic resistance in coagulase-negative Staphylococcus species isolated from 68 patients with acute post-cataract endophthalmitis. Clin Microbiol Infect. 2015. doi: 10.1016/j.cmi.2015.01.028.
127. Relhan N, Albini T, Pathengay A, et al. Bilateral endogenous endophthalmitis caused by vancomycin-resistant Staphylococcus epidermidis in a neonate. J Ophthalmic Inflamm Infect. 2015;5(1):1-4.
128. Dedania VS, Hale BP, Bhatnagar P. Endogenous endophthalmitis due to clinically vancomycin resistant Staphylococcus aureus. Retin Cases Brief Rep. 2015;9(1):59-60.
129. Liu GY. Molecular pathogenesis of Staphylococcus aureus infection. Ped Res. 2009;65:71R-7.
130. Jefferson K, Fowler V. Staphylococci in human disease. In: Archer G, editors. West Sussex: Wiley-Blackwell.
131. Cheung AL, Koomey JM, Butler CA, et al. Regulation of exoprotein expression in Staphylococcus aureus by a locus (sar) distinct from agr. Proc Natl Acad Sci. 1992;89: 6462-6.
132. Fournier B, Klier A, Rapoport G. The two-component system ArlS-ArlR is a regulator of virulence gene expression in Staphylococcus aureus. Mol Microbiol. 2001;41:247-61.
133. Morfeldt E, Janzon L, Arvidson S, et al. Cloning of a chromosomal locus (exp) which regulates the expression of several exoprotein genes in Staphylococcus aureus. Mol Gen Genet. 1988;211:435-40.
134. Peng HL, Novick RP, Kreiswirth B, et al. Cloning, characterization, and sequencing of an accessory gene regulator (agr) in Staphylococcus aureus. J Bacteriol. 1988;170:4365-72.
135. Yarwood JM, Schlievert PM. Quorum sensing in Staphylococcus infections. J Clin Invest. 2003;112(11):1620.
136. Novick RP. Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol Microbiol. 2003;48(6):1429-49.
137. Singh R, Ray P. Quorum sensing-mediated regulation of staphylococcal virulence and antibiotic resistance. Future Microbiol. 2014;9(5):669-81.
138. Rechtin TM, Gillaspy AF, Schumacher MA, et al. Characterization of the SarA virulence gene regulator of Staphylococcus aureus. Mol Microbiol. 1999;33:307-16.
139. Dunman PM, Murphy E, Haney S, et al. Transcription profiling-based identification of Staphylococcus aureus genes regulated by the agr and/or sarA loci. J Bacteriol. 2001;183:7341-53.
140. Chien Y, Manna AC, Projan SJ, et al. SarA, a global regulator of virulence determinants in Staphylococcus aureus, binds to a conserved motif essential for sar-dependent gene regulation. J Biol Chem. 1999;274:37169-76.
141. Vuong C, Saenz HL, Gotz F, et al. Impact of the agr quorum-sensing system on adherence to polystyrene in Staphylococcus aureus. J Infect Dis. 2000;182:1688-93.
142. Beenken KE, Mrak LN, Griffin LM, et al. Epistatic relationships between sarA and agr in Staphylococcus aureus biofilm formation. PLoS One. 2010;5:e10790.
143. Giraudo AT, Calzolari A, Cataldi AA, et al. The sae locus of Staphylococcus aureus encodes a two-component regulatory system. FEMS Microbiol Lett. 1999;177:15-22.
144. Voyich JM, Vuong C, DeWald M, et al. The SaeR/S gene regulatory system is essential for innate immune evasion by Staphylococcus aureus. J Infect Dis. 2009;199(11):1698-706.
145. Smeltzer MS, Hart ME, Iandolo JJ. Phenotypic characterization of xpr, a global regulator of extracellular virulence factors in Staphylococcus aureus. Infect Immun. 1993;61: 919-25.
146. Regassa LB, Betley MJ. Alkaline pH decreases expression of the accessory gene regulator (agr) in Staphylococcus aureus. J Bacteriol. 1992;174(15):5095-100.
147. Giese MJ, Berliner JA, Riesner A, et al. A comparison of the early inflammatory effects of an agr-/sar versus a wild type strain of Staphylococcus aureus in a rat model of endophthalmitis. Curr Eye Res. 1999;18:177-85.
148. Callegan MC, Engelbert M, Parke DW, et al. Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions. Clin Microbiol Rev. 2002;15(1):111-24.
149. Coykendall AL. Classification and identification of the viridans streptococci. Clin Microbiol Rev. 1989;2:315-28.
150. Mao LK, Flynn Jr HW, Miller D, et al. Endophthalmitis caused by streptococcal species. Arch Ophthalmol. 1992;110:798-801.
151. Harrison SA, Bateman JB. Endogenous endophthalmitis caused by Streptococcus mitis. Am J Ophthalmol. 1997;123:260-1.
152. Chen E, Lin MY, Cox J, et al. Endophthalmitis after intravitreal injection: the importance of viridans streptococci. Retina. 2011;31(8):1525-33.
153. Blum-Hareuveni T, Rehany U, Rumelt S. Devastating endophthalmitis following penetrating ocular injury during night sleep from orthodontic headgear: case report and literature review. Graefes Arch Clin Exp Ophthalmol. 2006;244(2):253-8.
154. Sahin O. Ocular complications of endocarditis. INTECH Open Access Publisher; Rijeka, Croatia; 2012.
155. Lamont M, Booth A. Post-traumatic endophthalmitis following penetrating injury with dental needle. Eye. 2006;20(8):981-2.
156. Song A, Scott IU, Flynn MHW, et al. Delayed-onset bleb-associated endophthalmitis: clinical features and visual acuity outcomes. Ophthalmology. 2002;109(5):985-91.
157. Leng T, Miller D, Flynn Jr HW, et al. Delayed-onset bleb-associated endophthalmitis (1996-2008): causative organisms and visual acuity outcomes. Retina. 2011;31:344-52.
158. Jedrzejas MJ. Pneumococcal virulence factors: structure and function. Microbiol Mol Biol Rev. 2001;65:187-207.
159. Alouf JE. Cholesterol-binding cytolytic protein toxins. Inter J Med Microbiol. 2000;290(4):351-6.
160. Palmer M. The family of thiol-activated, cholesterol-binding cytolysins. Toxicon. 2001;39(11):1681-9.
161. Ng EW, Samiy N, Rubins JB, et al. Implication of pneumolysin as a virulence factor in Streptococcus pneumoniae endophthalmitis. Retina. 1997;17(6):521-9.
162. Ng EW, Costa JR, Samiy N, et al. Contribution of pneumolysin and autolysin to the pathogenesis of experimental pneumococcal endophthalmitis. Retina. 2002;22(5):622-32.
163. Tuomanen E, Liu H, Hengstler B, et al. The induction of meningeal inflammation by components of the pneumococcal cell wall. J Infect Dis. 1985;151:859-68.
164. Tuomanen E, Tomasz A, Hengstler B, et al. The relative role of bacterial cell wall and capsule in the induction of inflammation in pneumococcal meningitis. J Infect Dis. 1985;151:535-40.
165. Johnson MK. Cellular location of pneumolysin. FEMS Microbiol Lett. 1977;2:243-5.
166. Mitchell TJ, Alexander JE, Morgan PJ, et al. Molecular analysis of virulence factors of Streptococcus pneumoniae. J Appl Microbiol. 1997;83:62S-71.
167. Johnson SE, Rubin L, Romero-Steiner S, et al. Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae. J Infect Dis. 1999;180:133-40.
168. Kadioglu A, Taylor S, Iannelli F, et al. Upper and lower respiratory tract infection by Streptococcus pneumoniae is affected by pneumolysin deficiency and differences in capsule type. Infect Immun. 2002;70:2886-90.
169. Llull D, Lopez R, Garcia E. Genetic bases and medical relevance of capsular polysaccharide biosynthesis in pathogenic streptococci. Curr Mol Med. 2001;1:475-91.
170. Magee AD, Yother J. Requirement for capsule in colonization by Streptococcus pneumoniae. Infect Immun. 2001;69:3755-61.
171. Norcross EW, Tullos NA, Taylor SD, et al. Assessment of Streptococcus pneumoniae capsule in conjunctivitis and keratitis in vivo neuraminidase activity increases in non-encapsulated pneumococci following conjunctival infection. Curr Eye Res. 2010;35(9):787-98.
172. Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev. 1998;11(4):589-603.
173. Yu WL, Ko WC, Cheng KC, et al. Association between rmpA and magA genes and clinical syndromes caused by Klebsiella pneumoniae in Taiwan. Clin Infect Dis. 2006;42(10):1351-8.
174. Fang CT, Chuang YP, Shun CT, et al. A novel virulence gene in Klebsiella pneumoniae causing primary liver abscess and septic metastatic complications. J Exp Med. 2004;199:697-705.
175. Wiskur BJ, Hunt JJ, Callegan MC. Hypermucoviscosity as a virulence factor in experimental Klebsiella pneumoniae endophthalmitis. Invest Ophthalmol Vis Sci. 2008;49(11): 4931-8.
176. Hunt JJ, Wang JT, Callegan MC. Contribution of mucoviscosity-associated gene A (magA) to virulence in experimental Klebsiella pneumoniae endophthalmitis. Invest Ophthalmol Vis Sci. 2011;52(9):6860-6.
177. Coburn PS, Wiskur BJ, Christy E, et al. The diabetic ocular environment facilitates the development of endogenous bacterial endophthalmitis. Invest Ophthalmol Vis Sci. 2012;53(12):7426-31.
178. Eifrig CW, Scott IU, Flynn HW, et al. Endophthalmitis caused by Pseudomonas aeruginosa. Ophthalmology. 2003;110(9):1714-7.
179. Pinna A, Usai D, Sechi LA, et al. An outbreak of post-cataract surgery endophthalmitis caused by Pseudomonas aeruginosa. Ophthalmology. 2009;116(12):2321-6.
180. Chen KJ, Sun MH, Lai CC, et al. Endophthalmitis caused by Pseudomonas aeruginosa in Taiwan. Retina. 2011;31(6):1193-8.
181. Goldstein EJ, Hanscom TA. Postoperative endophthalmitis. Clin Infect Dis. 2004;38(4):542-6.
182. Forster RK. Experimental postoperative endophthalmitis. Tr Am Ophthalmol Soc. 1992;90:505-59.
183. Alfaro D, Davis J, Kim S, et al. Experimental Bacillus cereus post-traumatic endophthalmitis and treatment with ciprofloxacin. Br J Ophthalmol. 1996;80:755-8.
184. Alfaro D, Hudson S, Kasowski E, et al. Experimental pseudomonal posttraumatic endophthalmitis in a swine model. Treatment with ceftazidime, amikacin and imipenem. Retina. 1997;17:139-45.
185. Aizuss DH, Mondino BJ, Sumner HL, et al. The complement system and host defense against Pseudomonas endophthalmitis. Invest Ophthalmol Vis Sci. 1985;26:1262-6.
186. Ramadan RT, Ramirez R, Novosad BD, et al. Acute inflammation and loss of retinal architecture and function during experimental Bacillus endophthalmitis. Curr Eye Res. 2006;31(11):955-65.
187. Chang JH, McCluskey PJ, Wakefield D. Recent advances in Toll-like receptors and anterior uveitis. Clin Exp Ophthalmol. 2012;40(8):821-8.
188. Mohammed I, Abedin A, Tsintzas K, et al. Increased expression of hepcidin and toll-like receptors 8 and 10 in viral keratitis. Cornea. 2011;30:899-904.
189. Huang X, Barrett RP, McClellan SA, et al. Silencing Toll-like receptor-9 in Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci. 2005;46:4209-16.
190. Yuan X, Wilhelmus KR. Toll-like receptors involved in the pathogenesis of experimental Candida albicans keratitis. Invest Ophthalmol Vis Sci. 2010;51:2094-100.
191. Zhao J, Wu XY, Fu-Shin XY. Activation of Toll-like receptors 2 and 4 in Aspergillus fumigatus keratitis. Innat Immun. 2009;15:155-68.
192. Allensworth JJ, Planck SR, Rosenbaum JT, et al. Investigation of the differential potentials of TLR agonists to elicit uveitis in mice. J Leukoc Biol. 2011;90:1159-66.
193. Kumar A, Singh CN, Glybina IV, et al. Toll-like receptor 2 ligand-induced protection against bacterial endophthalmitis. J Infect Dis. 2010;201:255-63.
194. Kochan T, Singla A, Tosi J, et al. Toll-like receptor 2 ligand pretreatment attenuates retinal microglial inflammatory response but enhances phagocytic activity toward Staphylococcus aureus. Infect Immun. 2012;80(6):2076-88.
195. Kumar A, Gao N, Standiford TJ, et al. Topical flagellin protects the injured corneas from Pseudomonas aeruginosa infection. Microbes Infect. 2010;12(12):978-89.
196. Talreja D, Singh PK, Kumar A. In vivo role of TLR2 and MyD88 signaling in eliciting innate immune responses in Staphylococcal endophthalmitis. Invest Ophthalmol Vis Sci. 2015;56(3):1719-32.
197. Novosad BD, Astley RA, Callegan MC. Role of toll-like receptor (TLR) 2 in experimental Bacillus cereus endophthalmitis. PLoS One. 2011;6(12):e28619.
198. Parkunan SM, Astley R, Callegan MC. Role of TLR5 and Flagella in Bacillus intraocular infection. PLoS One. 2014;9(6):e100543.
199. Hunt JJ, Astley R, Wheatley N, et al. TLR4 contributes to the host response to Klebsiella intraocular infection. Curr Eye Res. 2014;39(8):790-802.
200. Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by toll-like receptor 5. Nature. 2001;410:1099.
201. Stockhammer OW, Zakrzewska A, Hegedûs Z, et al. Transcriptome profiling and functional analyses of the zebrafish embryonic innate immune response to Salmonella infection. J Immunol. 2009;182:5641.
202. Iqbal M, Philbin VJ, Withanage GSK, et al. Identification and functional characterization of chicken toll-like receptor 5 reveals a fundamental role in the biology of infection with Salmonella enterica serovar typhimurium. Infect Immun. 2005;73:2344.
203. Blohmke CJ, Park J, Hirschfeld AF, et al. TLR5 as an anti-inflammatory target and modifier gene in cystic fibrosis. J Immunol. 2010;185(12):7731-8.
204. Chamberlain ND, Vila OM, Volin MV, et al. TLR5, a novel and unidentified inflammatory mediator in rheumatoid arthritis that correlates with disease activity score and joint TNF-α levels. J Immunol. 2012;189(1):475-83.
205. Vijay-Kumar M, Sanders CJ, Taylor RT, et al. Deletion of TLR5 results in spontaneous colitis in mice. J Clin Invest. 2007;117:3909-21.
206. Kumar A, Hazlett LD, Yu FS. Flagellin suppresses the inflammatory response and enhances bacterial clearance in a murine Model of Pseudomonas aeruginosa keratitis. Infect Immun. 2008;76(1):89-96.
207. Parkunan SM, Randall CB, Coburn PS, et al. Unexpected roles for toll-like receptor 4 and TRIF in intraocular infection with gram-positive bacteria. Infect Immun. 2015;83(10):3926-36.
208. Ramadan RT, Moyer AL, Callegan MC. A role for tumor necrosis factor-α in experimental Bacillus cereus endophthalmitis pathogenesis. Invest Ophthalmol Vis Sci. 2008;49(10):4482-9.
209. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol. 2011;30(1):16-34.
210. Rosenzweig HL, Planck SR, Rosenbaum JT. NLRs in immune privileged sites. Curr Opin Pharmacol. 2011;11(4):423-8.
211. Rosenzweig HL, Martin TM, Planck SR, et al. Activation of NOD2 in vivo induces IL-1β production in the eye via caspase-1 but results in ocular inflammation independently of IL-1 signaling. J Leuk Biol. 2008;84(2):529-36.
212. Rubartelli A, Lotze MT. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol. 2007;28(10):429-36.
213. Yamaguchi K, Gaur VP, Tytell M, et al. Ocular distribution of 70-kDa heat-shock protein in rats with normal and dystrophic retinas. Cell Tissue Res. 1991;264:497-506.
214. Kumagami T, Kato S, Ishikura R, et al. Expression of stress-response protein 60 in iritis associated with experimental autoimmune encephalomyelitis. Jpn J Ophthalmol. 1999;43:458-65.
215. Rocha G, Duclos A, Chalifour LE, et al. Analysis of gene expression during experimental uveitis in the rabbit. Can J Ophthalmol. 1996;31:228-33.
216. Pachydaki SI, Tari SR, Lee SE, et al. Upregulation of RAGE and its ligands in proliferative retinal disease. Exp Eye Res. 2006;82:807-15.
217. Giese MJ, Sumner HL, Berliner JA, et al. Cytokine expression in a rat model of Staphylococcus aureus endophthalmitis. Invest Ophthalmol Vis Sci. 1998;39(13):2785-90.
218. Ravindranath RM, Mondino BJ, Adamu SA, et al. Immunopathologic features of Staphylococcus aureus endophthalmitis in the rat. Invest Ophthalmol Vis Sci. 1995;36(12):2482-91.
219. Giese MJ, Rayner SA, Fardin B, et al. Mitigation of neutrophil infiltration in a rat model of early Staphylococcus aureus endophthalmitis. Invest Ophthalmol Vis Sci. 2003;44(7):3077-82.
220. Petropoulos IK, Vantzou CV, Lamari FN, et al. Expression of TNF-α, IL-1β, and IFN-γ in Staphylococcus epidermidis slime-positive experimental endophthalmitis is closely related to clinical inflammatory scores. Graefes Arch Clin Exp Ophthalmol. 2006;244(10):1322-8.
221. Moyer AL, Ramadan RT, Novosad BD, et al. Bacillus cereus -induced permeability of the blood-ocular barrier during experimental endophthalmitis. Invest Ophthalmol Vis Sci. 2009;50(8):3783-93.
222. Engstrom RE, Mondino BJ, Glasgow BJ, et al. Immune response to Staphylococcus aureus endophthalmitis in a rabbit model. Invest Ophthalmol Vis Sci. 1991;32(5):1523-33.
223. Pleyer U, Mondino BJ, Adamu SA, et al. Immune response to Staphylococcus epidermidis - induced endophthalmitis in a rabbit model. Invest Ophthalmol Vis Sci. 1992;33(9):2650-63.
224. Sonnen AFP, Henneke P. Structural biology of the membrane attack complex. In: MACPF/CDC proteins-agents of defence, attack and invasion. Dordrecht: Springer; 2014. p. 83-116.
225. Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res. 2010;20(1):34-50.
226. Tosi MF. Innate immune responses to infection. J Allergy Clin Immunol. 2005;116:241-9.
227. Liszewski MK, Farries TC, Lublin DM, et al. Control of the complement system. Adv Immunol. 1996;61:201-83.
228. Nicholson-Weller A. Decay accelerating factor (CD55). Curr Top Microbiol Immunol. 1992;178:7-30.
229. Liszewski MK, Post TW, Atkinson JP. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Ann Rev Immunol. 1991;9:431-55.
230. Holguin MH, Parker CJ. Membrane inhibitor of reactive lysis. Curr Top Microbiol Imunol. 1992;178:61-85.
231. Bora NS, Gobleman CL, Atkinson JP, et al. Differential expression of the complement regulatory proteins in the human eye. Invest Ophthalmol Vis Sci. 1993;34:3579-84.
232. Bardenstein DS, Dietz Y, Lass JH, et al. Localization of the complement membrane attack complex inhibitor (CD59) in human conjunctiva and lacrimal gland. Curr Eye Res. 1994;13:851-5.
233. Sohn JH, Kaplan HJ, Suk HJ, et al. Chronic low level of complement activation within the eye is controlled by intraocular complement regulatory proteins. Invest Ophthalmol Vis Sci. 2000;41:3492-502.
234. Chandler JW, Leder R, Kaufman HE, et al. Quantitative determinations of complement components and immunoglobulins in tears and aqueous humor. Invest Ophthalmol Vis Sci. 1974;13:151-3.
235. Mondino BJ, Rao H. Hemolytic complement activity in aqueous humor. Arch Ophthalmol. 1983;101:465-8.
236. Mondino BJ, Sidikaro Y, Sumner HL. Anaphylatoxin levels in human vitreous humor. Invest Ophthalmol Vis Sci. 1988;29:1195-8.
237. Giese MJ, Mondino BJ, Glasgow BJ, et al. Complement system and host defense against Staphylococcal endophthalmitis. Invest Ophthalmol Vis Sci. 1994;35(3):1026-32.
238. Engelbert M, Gilmore MS. Fas ligand but not complement is critical for control of experimental Staphylococcus aureus endophthalmitis. Invest Ophthalmol Vis Sci. 2005;46:2479-86.
239. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nucleus DNA fragmentation. J Cell Biol. 1992;119:493-501.
240. Griffith TS, Brunner T, Fletcher SM, et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270(5239):1189-92.
241. Pharmakakis NM, Petropoulos IK, Georgakopoulos CK, et al. Apoptotic mechanisms within the retina in Staphylococcus epidermidis experimental endophthalmitis. Graefes Arch Clin Exp Ophthalmol. 2009;247(5):667-74.
242. Gregory MS, Repp AC, Holhbaum AM, et al. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege. J Immunol. 2002;169:2727-35.
243. Wiskur BJ, Robinson ML, Farrand AJ, et al. Toward improving therapeutic regimens for Bacillus endophthalmitis. Invest Ophthalmol Vis Sci. 2008;49(4):1480-7.
244. Callegan MC, Guess S, Wheatley NR, et al. Efficacy of vitrectomy in improving the outcome of Bacillus cereus endophthalmitis. Retina. 2011;31(8):1518-24.